DGCI approves Phase IIIII clinical trials of Oxford University vaccine by Serum Institute, Pune
The Drugs Controller General of India has given approval to Serum Institute of India, Pune to conduct Phase IIIII clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.
This will hasten the development of the COVID-19 vaccine. Union Health Ministry said, India continues to improve the Case Fatality Rate (CFR), and maintain its global position of having one of the lowest COVID fatalities rates.
With a further fall, the current CFR touched 2.11 per cent today.
The management strategy of COVID-19 also focuses on early detection and isolation of cases with seamless patient management and prioritising care of the high-risk population, leading to increase in recoveries across the country.
The Ministry said, India has seen more than 40,574 patients recovered in the last 24 hours.
This takes the total recoveries to 11,86,203 and recovery rate to 65.77 per cent amongst COVID-19 patients.
With improving daily recovery number, the gap between the recovered cases and the active cases has increased to more than 6 lakh.
The actual active case load is over 5,79,000 and all are under medical supervision.